Search Results
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
pool across multiple continents. Ateganosine is a first-in-class investigational telomere-targeting agent that induces telomerase-dependent telomeric DNA modification and activates both innate and adaptive immune responses, currently being developed as a second or later line of treatment for NSCLC patients
More news about: USA News Group
Oct 07, 2025, 08:30 ET TOTE.AI SHOWCASES FIRST AI-NATIVE POINT-OF-SALE SYSTEM FOR FUEL & CONVENIENCE STORES AT NACS 2025, CHICAGO
Why A POS That's AI-Native Matters AI-native means intelligence is baked into the DNA of the system, not bolted on after the fact. Bolt-ons are simple chat bots that can't keep up with real-time analytics, personalization, or omni-channel
More news about: Tote.ai
Oct 07, 2025, 08:01 ET PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement
subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer
More news about: PAVmed Inc.
Oct 07, 2025, 08:00 ET RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
and plans to begin the Phase I clinical trial in 2027. RG0401 aims to cure refractory RA by treating its HLA source. With a single precision edit to a DNA marker of the HLA gene, RG0401 substantially quiets only one of a patient's HLA alleles while leaving a healthy immune system intact. The therapy is
More news about: RheumaGen, Inc.
Oct 07, 2025, 07:30 ET Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant
More news about: SOLIGENIX, INC.
Oct 06, 2025, 18:08 ET Jeep 永不遺棄任何人，即使在電子遊戲中亦然。
「玩家習慣在卡住時，重新啟動遊戲。Jeep 玩家不會重新啟動，他們選擇重組，」Publicis Middle East 執行創意總 Tuki Ghiassi 表示：「Rescue Squad 救援小隊將遊戲中最大的沮喪之一，轉化為驚喜和社群聯繫。這是純粹的 Jeep DNA。」 前一秒，你還困在原地；下一秒，就見最愛的遊戲角色開著 Jeep 吉普車現身救援，這般驚喜令人措手不及。 Rescue Squad 救援小隊緊接在 8 月，於沙地阿拉伯舉辦的 Esports World
More news about: Jeep Middle East
Oct 06, 2025, 17:37 ET DER JEEP LÄSST NIEMANDEN ZURÜCK. NICHT EINMAL IN VIDEOSPIELEN.
weiterhin innovativ ist",, sagte Melhem Najm, Regional Chief Marketing Officer, Stellantis Middle East and Africa. „Wir präsentieren die 4x4-DNA von Jeep in einem völlig neuen Raum und bringen sie gleichzeitig mit realen Abenteuern und Geschäftszielen in Verbindung."
More news about: Jeep Middle East
Oct 06, 2025, 17:25 ET A JEEP NUNCA DEIXA NINGUÉM PARA TRÁS. MESMO EM VIDEOGAMES.
veículos, mas em experiências", disse Melhem Najm, Diretor Regional de Marketing da Stellantis Oriente Médio e África. "Estamos apresentando o DNA 4x4 da Jeep em um espaço completamente novo, enquanto o conectamos à aventura do mundo real e aos objetivos de negócios." "O
More news about: Jeep Middle East
Oct 06, 2025, 17:18 ET JEEP NEVER LEAVES ANYONE BEHIND. EVEN IN VIDEOGAMES.
vehicles but in experiences," said Melhem Najm, Regional Chief Marketing Officer, Stellantis Middle East and Africa. "We are showcasing Jeep's 4x4 DNA in a completely new space, while connecting it back to real-world adventure and business objectives." "Rescue Squad isn't
More news about: Jeep Middle East
Oct 06, 2025, 17:15 ET JEEP NEVER LEAVES ANYONE BEHIND. EVEN IN VIDEOGAMES.
vehicles but in experiences," said Melhem Najm, Regional Chief Marketing Officer, Stellantis Middle East and Africa. "We are showcasing Jeep's 4x4 DNA in a completely new space, while connecting it back to real-world adventure and business objectives." "Rescue Squad isn't
More news about: Jeep Middle East
Oct 06, 2025, 16:01 ET PM360 2025 Trailblazer Awards Winners Announced: Top Companies, Marketers, CEOs, Products, and Initiatives Honored at Gala, Sept. 30th
(Sumitomo Pharma America and Klick Health) SOCIAL MEDIA CAMPAIGN SILVER WINNER:Rated RSV (Pfizer, dna Communications, and Weber Shandwick) SOCIAL MEDIA CAMPAIGN GOLD WINNER:Empathy in Action: How
More news about: PM360
Oct 06, 2025, 14:19 ET IMA Medical Group Joins Millennium Physician Group, Strengthening Value-Based Care Across Central Florida
employees, and to serve communities effectively. "This partnership unites two organizations that share the same DNA," said Tesha Simpson, Chief Executive Officer of Millennium Physician Group. "IMA's dedication to their patients, employees, clinicians, and communities
More news about: Millennium Physician Group
Oct 06, 2025, 10:17 ET Pendulum Therapeutics Appoints Former Starbucks CEO Laxman Narasimhan to Board of Directors
accelerating this vision." Backed by more than a decade of rigorous R&D - including deep expertise in DNA sequencing, anaerobic manufacturing, and clinical validation - Pendulum brings a level of credibility unmatched in the field. Pendulum's breakthroughs
More news about: Pendulum Therapeutics
Oct 06, 2025, 08:37 ET Virtual Field Launches DICOM 360 Sync; Transforming Eye Exam Workflows with Instant, Automatic, Error-Free Interoperability
A Track Record of Innovation Virtual Field isn't new to innovation — it's in the company's DNA. From being the first to deliver portable, affordable visual field testing to continuously expanding diagnostic capabilities and automating complex workflows,
More news about: Virtual Field
Oct 06, 2025, 08:30 ET Novel Long RNA Manufacturing Approaches for Advancing RNA Therapeutics, Upcoming Webinar Hosted by Xtalks
ligase. To ligate RNAs with this enzyme, it is necessary to form a nick-like structure at the joining site using complementary DNA splints. When two sequences of RNA are used, DNA splints that form complementary strands of several to 20 bases around the joining site are designed. However,
More news about: Xtalks
Oct 06, 2025, 08:00 ET Flourish Research Establishes Meaningful Presence in Oncology with Strategic Investment in Valkyrie Clinical Trials
chapter for Valkyrie as we advance our mission to expand access to the most effective cancer therapies for patients of all backgrounds. We share a common DNA and by utilizing Flourish's national network and infrastructure, we look forward to accelerating our growth and broadening access to innovative oncology
More news about: Flourish Research
Oct 04, 2025, 03:24 ET A Diamond is Forever celebrates Desert diamonds
Brands & Diamond Desirability, said: "Tonight reminds us of the magic, myth and wonder inherent in the DNA of natural diamonds. Today's consumers have a need to convey their individuality while continuing to honor their deepest bonds and connections with the
More news about: De Beers Group
Oct 03, 2025, 12:56 ET Long John Silver's Unveils Bold New Look to Spotlight Chicken
"This brand was built on making the coastal experience accessible to everyone, so seafood will always be part of our DNA," said Caudill. "But chicken is also part of our heritage—and a big part of our future—so it deserves its rightful place on our logo, our menu,
More news about: Long John Silver’s
Oct 03, 2025, 09:07 ET Halsey Festival Draws Thousands to Newark on September 18 with Music, Food and Community Celebration
Stokes, Managing Director, Corporate & Government Affairs of United Airlines added: "Giving back to the communities we live in and serve is in our DNA at United. We're proud to sponsor Halsey Fest and help showcase Newark's businesses, arts, and local talent to residents and visitors alike. Newark's
More news about: Newark Alliance
Oct 03, 2025, 08:37 ET Synevit Highlights Comprehensive Vitamin B Complex Heading into Shorter Days and Colder Weather
B9 (Folate) – Helps with DNA synthesis, supports pregnancy, growth, and development.
More news about: Synevit
Oct 03, 2025, 03:00 ET Germany's Offshore Centers in India Expand to 150+ Centers and 130,000+ Talent, Driving ER&D and Digital Transformation
Mohammed Faraz Khan, Partner and Head – EMEA, Zinnov. "By combining their engineering DNA with India's digital depth, Mittelstand firms are building platforms that drive agility, global relevance, and future-ready growth."
More news about: Zinnov
Oct 03, 2025, 03:00 ET Germany's Offshore Centers in India Expand to 150+ Centers and 130,000+ Talent, Driving ER&D and Digital Transformation
Mohammed Faraz Khan, Partner and Head – EMEA, Zinnov. "By combining their engineering DNA with India's digital depth, Mittelstand firms are building platforms that drive agility, global relevance, and future-ready growth."
More news about: Zinnov
Oct 03, 2025, 03:00 ET Deutschlands Offshore-Zentren in Indien expandieren auf über 150 Zentren mit über 130 000 Talente und treiben ER&D und digitale Transformation voran
Mohammed Faraz Khan, Partner und Leiter – EMEA, Zinnov hinzu. „Durch die Kombination ihrer technischen DNA mit der digitalen Tiefe Indiens bauen mittelständische Unternehmen Plattformen auf, die Agilität, globale Relevanz und zukunftsfähiges Wachstum fördern."
More news about: Zinnov
Oct 03, 2025, 02:00 ET The Department of Clinical and Molecular Medicine of Sapienza University of Rome, Takis and Tethis start a collaboration to advance HER3-targeted therapies and diagnostics
implementation of a number of innovative technologies, including DNA delivery. Takis is actively advancing humanized monoclonal antibodies and bispecifics for oncology and infectious diseases, including COVID-19. The company has also developed COVID-eVax, a DNA-based vaccine against SARS-CoV-2, and continues to apply
More news about: Tethis S.p.A.
Oct 03, 2025, 02:00 ET Il Dipartimento di Medicina Clinica e Molecolare di Sapienza Università di Roma, Takis e Tethis iniziano una collaborazione per promuovere lo sviluppo di terapie e diagnostica mirate contro HER3
tecnologie innovative, tra cui il trasferimento di DNA. Takis sta attivamente sviluppando anticorpi monoclonali e molecole bispecifiche per l'oncologia e le malattie infettive, compreso il COVID-19. L'azienda ha inoltre sviluppato COVID-eVax, un vaccino a DNA contro il SARS-CoV-2, e continua ad applicare
More news about: Tethis S.p.A.